325413

Analysis

NAICS 325413 is the 2022 national industry for in-vitro diagnostic substance manufacturing, part of 32541 (Pharmaceutical and Medicine Manufacturing). Census lists 13 example activities under it in the official index.

County Business Patterns counts 267 US establishments in this code in 2023, employing 45,459 people at an average annual payroll of $115,404 per employee (90th percentile of national industries). 19% of the establishments have fewer than five employees, which points to larger operations.

Between 2018 and 2023 the number of establishments grew 13% and employment rose 59%. The 2018 count used NAICS 2017, so part of a large move can come from codes being redefined rather than from businesses opening or closing.

By establishments it ranks 4th of the 4 codes at this level within Pharmaceutical and Medicine Manufacturing, with 9.2% of them.

Its index entries, the activities Census uses to assign businesses to this code, include blood derivative in-vitro diagnostic substances…, blood glucose test kits manufacturing, coagulation in-vitro diagnostic substances manufacturing and cytology and histology in-vitro diagnostic substances…, among 13 in all.

Its goods appear in 14 statistical lines of the US tariff schedule, mostly under headings 3822 (diagnostic or laboratory reagents on a backing, prepared…), 3002 (human blood; animal blood prepared for therapeutic…) and 3006 (pharmaceutical goods specified in note 4 to this chapter). That link is how import data is matched to domestic producers, for example in trade-remedy cases.